Latest Share Based Payments News

Neu Horizon Uranium Limited, formerly Tasmania Data Infrastructure, has pivoted from bitcoin mining to uranium exploration in Sweden, reporting a reduced loss for FY25 while progressing towards an ASX listing and expanding its footprint into Canadian mineral claims.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

IRIS Metals posted a $22.3 million loss for FY26, driven by major impairments on exploration assets and elevated share-based payments. The company pivots away from Edison and Tin Mountain projects, focusing on lithium-rubidium in South Dakota and tungsten in Montana.

Daly Resources has posted a $352,743 loss for FY2025 amid aggressive expansion of its exploration portfolio, including the acquisition of the Huckitta and North Batten projects. The company is gearing up for a $10 million IPO in 2026 to fund its base metals and fluorite exploration ambitions.

Little Green Pharma (ASX:LGP) posted a 15.3% revenue increase to AUD 42.5 million in FY2026, driven by European market expansion, yet recorded a $1.4 million loss after tax impacted by significant inventory write-downs.

Energy One Limited reveals solid sales momentum and strategic AI integration under new CEO Ben Tranier, despite slight ARR timing delays and ongoing market complexity.

Catapult Sports Ltd (ASX:CAT) delivered a 20.8% revenue increase to US$140.7 million in FY26, driven by strong SaaS growth and strategic acquisitions, while management EBITDA surged 67%. Despite this, the company reported a net loss of US$24 million, impacted by non-cash expenses and acquisition costs.

Titan Minerals boosts its Dynasty Gold Project resource to 3.9 million ounces of gold and 26.1 million ounces of silver, driven by extensive drilling at Cerro Verde and discovery of porphyry mineralisation at Kaliman. A major 30,000m drilling campaign is planned for 2026 alongside advancing feasibility studies.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Merino & Co. Limited reported a 60.5% drop in revenue and a 28.2% increase in net loss for the half-year ending December 2025, reflecting a strategic investment phase aimed at future growth. The company is expanding production capacity and building inventory ahead of wholesale expansion, signaling a pivot towards revenue acceleration.

Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.